Literature DB >> 7929089

Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells.

H Hatakeyama1, I Miyamori, T Fujita, Y Takeda, R Takeda, H Yamamoto.   

Abstract

Mineralocorticoids have been suggested to act on blood vessels, leading to increased vasoreactivity and peripheral resistance. However, the site of their production has so far been believed to be only the adrenal cortex. Here, we show direct evidence that vascular cells per se are aldosteronogenic, possessing their own system that responds to the steroid. Using polymerase chain reaction after reverse transcription, the CYP11B2 mRNA encoding the key enzyme for the biosynthesis of aldosterone was detected in both endothelial cells and smooth muscle cells cultivated from human pulmonary artery. The aldosterone receptor (type 1 mineralocorticoid receptor) gene was also found to be expressed in smooth muscle cells and, to a lesser extent, in endothelial cells. CYP11B2 gene expression in smooth muscle cells was stimulated by angiotensin II, the effector peptide of the renin-angiotensin system. Furthermore, the angiotensin II-induced increase in [3H]leucine incorporation in smooth muscle cells was significantly enhanced by aldosterone but inhibited by ZK 91587, a type 1 mineralocorticoid receptor antagonist. This may indicate that vascular aldosterone participates in the angiotensin II-induced hypertrophy of vascular smooth muscle cells. The present study therefore provides the starting point for a novel understanding of the molecular basis of vascular remodeling and hypertension.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929089

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis.

Authors:  Xu Li; Ying Meng; Xi-Shan Yang; Ping-Sheng Wu; Shu-Mei Li; Wen-Yan Lai
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Aldosterone and vascular damage.

Authors:  D Duprez; M De Buyzere; E R Rietzschel; D L Clement
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 3.  Aldosterone antagonists in the treatment of hypertension and target organ damage.

Authors:  S Rajagopalan; B Pitt
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

4.  Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects.

Authors:  E Marie Freel; Loai A Shakerdi; Elaine C Friel; A Michael Wallace; Eleanor Davies; Robert Fraser; John M C Connell
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

Review 5.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature.

Authors:  Jennifer J DuPont; Iris Z Jaffe
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286

Review 6.  Vascular remodeling and mineralocorticoids.

Authors:  K T Weber; Y Sun; S E Campbell; S H Slight; V K Ganjam
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 7.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

Review 8.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 9.  Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.

Authors:  Adam P McGraw; Amy McCurley; Ioana R Preston; Iris Z Jaffe
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

Review 10.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.